These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

75 related items for PubMed ID: 20152524

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 3. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J.
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [Abstract] [Full Text] [Related]

  • 4. Targeting continued androgen receptor signaling in prostate cancer.
    Massard C, Fizazi K.
    Clin Cancer Res; 2011 Jun 15; 17(12):3876-83. PubMed ID: 21680543
    [Abstract] [Full Text] [Related]

  • 5. New drugs in prostate cancer.
    Armstrong AJ, Carducci MA.
    Curr Opin Urol; 2006 May 15; 16(3):138-45. PubMed ID: 16679849
    [Abstract] [Full Text] [Related]

  • 6. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME.
    Expert Rev Anticancer Ther; 2008 Sep 15; 8(9):1495-508. PubMed ID: 18759700
    [Abstract] [Full Text] [Related]

  • 7. Abiraterone acetate for castration resistant prostate cancer.
    Shah S, Ryan C.
    Expert Opin Investig Drugs; 2010 Apr 15; 19(4):563-70. PubMed ID: 20225998
    [Abstract] [Full Text] [Related]

  • 8. The role of fibroblast growth factors and their receptors in prostate cancer.
    Kwabi-Addo B, Ozen M, Ittmann M.
    Endocr Relat Cancer; 2004 Dec 15; 11(4):709-24. PubMed ID: 15613447
    [Abstract] [Full Text] [Related]

  • 9. Emerging treatment options for patients with castration-resistant prostate cancer.
    George D, Moul JW.
    Prostate; 2012 Feb 15; 72(3):338-49. PubMed ID: 21748753
    [Abstract] [Full Text] [Related]

  • 10. Novel targeted pro-apoptotic agents for the treatment of prostate cancer.
    Huang X, Zhang X, Farahvash B, Olumi AF.
    J Urol; 2007 Nov 15; 178(5):1846-54. PubMed ID: 17868738
    [Abstract] [Full Text] [Related]

  • 11. Insulin-Like Growth Factor (IGF) family and prostate cancer.
    Gennigens C, Menetrier-Caux C, Droz JP.
    Crit Rev Oncol Hematol; 2006 May 15; 58(2):124-45. PubMed ID: 16387509
    [Abstract] [Full Text] [Related]

  • 12. Combinatorial androgen receptor targeted therapy for prostate cancer.
    Singh P, Uzgare A, Litvinov I, Denmeade SR, Isaacs JT.
    Endocr Relat Cancer; 2006 Sep 15; 13(3):653-66. PubMed ID: 16954423
    [Abstract] [Full Text] [Related]

  • 13. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.
    Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T.
    Eur Urol; 2009 Oct 15; 56(4):594-605. PubMed ID: 19560857
    [Abstract] [Full Text] [Related]

  • 14. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S, Djelloul S, Raymond E.
    Semin Oncol; 2006 Aug 15; 33(4):407-20. PubMed ID: 16890796
    [Abstract] [Full Text] [Related]

  • 15. Mammalian target of rapamycin: a new target in prostate cancer.
    Rai JS, Henley MJ, Ratan HL.
    Urol Oncol; 2010 Aug 15; 28(2):134-8. PubMed ID: 19523861
    [Abstract] [Full Text] [Related]

  • 16. Targeting the apoptosis pathway in prostate cancer.
    Zielinski RR, Eigl BJ, Chi KN.
    Cancer J; 2013 Aug 15; 19(1):79-89. PubMed ID: 23337761
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein.
    Dorai T, Gehani N, Katz A.
    Mol Urol; 2000 Aug 15; 4(1):1-6. PubMed ID: 10851300
    [Abstract] [Full Text] [Related]

  • 18. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy.
    McCarty MF.
    Integr Cancer Ther; 2004 Dec 15; 3(4):349-80. PubMed ID: 15523106
    [Abstract] [Full Text] [Related]

  • 19. National cooperative group trials.
    Dipaola RS, Thompson IM.
    Urology; 2005 May 15; 65(5 Suppl):23-9; discussion 29. PubMed ID: 15885277
    [Abstract] [Full Text] [Related]

  • 20. Novel drugs targeting the androgen receptor pathway in prostate cancer.
    Mateo J, Smith A, Ong M, de Bono JS.
    Cancer Metastasis Rev; 2014 Sep 15; 33(2-3):567-79. PubMed ID: 24390422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.